The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

Frazor Edmondson, III Biography and Net Worth

Insider of Zai Lab

Frazor Titus Edmondson III is the Chief Legal Officer & Corp. Sec. at Zai Lab.

What is Frazor Titus Edmondson, III's net worth?: The estimated net worth of Frazor Titus Edmondson, III is at least $430,381.84 as of May 14th, 2024. Mr. Edmondson, III owns 16,408 shares of Zai Lab stock worth more than $430,382 as of November 21st. This net worth approximation does not reflect any other investments that Mr. Edmondson, III may own. Learn More about Frazor Titus Edmondson, III's net worth.
How do I contact Frazor Titus Edmondson, III?: The corporate mailing address for Mr. Edmondson, III and other Zai Lab executives is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. Zai Lab can also be reached via phone at 862161632588 and via email at [email protected]. Learn More on Frazor Titus Edmondson, III's contact information.
Has Frazor Titus Edmondson, III been buying or selling shares of Zai Lab?: Frazor Titus Edmondson, III has not been actively trading shares of Zai Lab within the last three months. Most recently, Frazor Titus Edmondson III sold 10,000 shares of the business's stock in a transaction on Tuesday, May 14th. The shares were sold at an average price of $21.33, for a transaction totalling $213,300.00. Following the completion of the sale, the insider now directly owns 16,408 shares of the company's stock, valued at $349,982.64. Learn More on Frazor Titus Edmondson, III's trading history.
Who are Zai Lab's active insiders?: Zai Lab's insider roster includes Rafael Amado (President, Head of Global Research and Development), Kai-Xian Chen (Director), Yajing Chen (CFO), William Cho (CFO), John Diekman (Director), Ying Du (CEO), Frazor Edmondson, III (Insider), Tao Fu (COO), William Lis (Director), Harald Reinhart (Insider), Joshua Smiley (Insider), and Peter Wirth (Director). Learn More on Zai Lab's active insiders.
Are insiders buying or selling shares of Zai Lab?: During the last twelve months, Zai Lab insiders bought shares 1 times. They purchased a total of 4,000 shares worth more than $119,600.00. During the last twelve months, insiders at the sold shares 15 times. They sold a total of 105,597 shares worth more than $2,125,230.82. The most recent insider tranaction occured on August, 16th when insider Joshua L Smiley sold 4,352 shares worth more than $72,547.84. Insiders at Zai Lab own 13.9% of the company. Learn More about insider trades at Zai Lab.
Information on this page was last updated on 8/16/2024.

Frazor Titus Edmondson, III Insider Trading History at Zai Lab

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/14/2024	Sell	10,000	$21.33	$213,300.00	16,408
4/2/2024	Sell	885	$16.15	$14,292.75	22,621
3/6/2023	Sell	7,965	$40.55	$322,980.75	19,400

Frazor Titus Edmondson, III Buying and Selling Activity at Zai Lab

Zai Lab Company Overview

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

Today's Range

Now: $26.23

$25.63

$26.77

50 Day Range

MA: $26.28

$20.34

$33.18

2 Week Range

Now: $26.23

$13.48

$36.60

Volume

1,384,654 shs

Average Volume

1,308,194 shs

Market Capitalization

$2.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.04

War on Elon Escalates…

From Porter & Company | Ad

A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

One company holds a near-total monopoly on it.